Loading...
•
Dec 31, 2022
TELA Bio Q4 2022 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2022.
Key Takeaways
TELA Bio reported a 39% increase in revenue for Q4 2022 compared to the same period in 2021, driven by commercial expansion, increased customer penetration, and stronger international sales. Gross profit also increased, while operating expenses led to a higher net loss compared to the previous year.
Revenue increased by 39% to $11.6 million compared to the same period in 2021.
Gross profit was $8.2 million, representing 70% of revenue, compared to 68% in the same period in 2021.
Operating expenses increased to $17.6 million due to higher salaries, employee-related expenses, increased travel, and consulting fees.
Net loss was $10.0 million, compared to a net loss of $8.6 million in the same period in 2021.
Forward Guidance
Full year 2023 revenue is projected to range from $60 million to $65 million, reflecting growth of 45% to 57% over full year 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...